Search results for "Patient management"

showing 10 items of 30 documents

The neurochaperonopathies: Anomalies of the chaperone system with pathogenic effects in neurodegenerative and neuromuscular disorders

2021

The chaperone (or chaperoning) system (CS) constitutes molecular chaperones, co-chaperones, and chaperone co-factors, interactors and receptors, and its canonical role is protein quality control. A malfunction of the CS may cause diseases, known as the chaperonopathies. These are caused by qualitatively and/or quantitatively abnormal molecular chaperones. Since the CS is ubiquitous, chaperonopathies are systemic, affecting various tissues and organs, playing an etiologic-pathogenic role in diverse conditions. In this review, we focus on chaperonopathies involved in the pathogenic mechanisms of diseases of the central and peripheral nervous systems: the neurochaperonopathies (NCPs). Genetic …

0301 basic medicineHspsDiseasechaperonopathieslcsh:Technologylcsh:Chemistry03 medical and health sciences0302 clinical medicineneurochaperonopathieschaperone systemchaperonotherapy.medicineGeneral Materials ScienceReceptorInstrumentationGenelcsh:QH301-705.5Fluid Flow and Transfer Processesbiologylcsh:TSettore BIO/16 - Anatomia UmanaProcess Chemistry and TechnologyNeurodegenerationmolecular chaperonesnervous systemGeneral Engineeringmedicine.diseaseHsp90lcsh:QC1-999Computer Science ApplicationsCell biologyPatient management030104 developmental biologylcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040Chaperone (protein)biology.proteinChaperone system ChaperonopathiesChaperonotherapy Hsps Molecular chaperones Nervous system Neurochaperonopathies Neurodegeneration neuromuscular disorderHSP60lcsh:Engineering (General). Civil engineering (General)030217 neurology & neurosurgerylcsh:Physics
researchProduct

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

2016

Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for th…

0301 basic medicineOncologyCancer ResearchmTOR inhibitorEndocrinology Diabetes and MetabolismNeuroendocrine tumorsAntineoplastic Agent0302 clinical medicineEndocrinologyNeuroendocrine tumoursneuroendocrine tumourTreatment resistanceMTOR inhibitorsTumorMedical treatmentTOR Serine-Threonine KinasesDiscovery and development of mTOR inhibitorsResponse to treatmentPatient managementDiabetes and MetabolismNeuroendocrine TumorsOncology030220 oncology & carcinogenesisResponse to treatmentNeuroendocrine TumorHumanMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Endocrinology Diabetes and Metabolism; Oncology; Endocrinology; Cancer ResearchDiagnostic Imagingmedicine.medical_specialtyProtein Kinase InhibitorEarly detectionpredictorAntineoplastic AgentsMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Endocrinology; Oncology; Cancer Research; Endocrinology Diabetes and MetabolismBiologyNO03 medical and health sciencesmTOR inhibitors; neuroendocrine tumours; predictors; response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine KinasesInternal medicineBiomarkers TumormedicineAnimalsHumansmTOR inhibitorsneuroendocrine tumourspredictorsresponse to treatmentProtein Kinase InhibitorsmTOR inhibitors neuroendocrine tumours predictors response to treatmentAnimalPredictorsmedicine.disease030104 developmental biologyImmunologyBiomarkersResource utilizationEndocrine-Related Cancer
researchProduct

Negative biopsy of focal hepatic lesions: Decision tree model for patient management

2019

OBJECTIVE. The purpose of this study was to investigate patient- and procedure-related variables affecting the false-negative rate of ultrasound (US)-guided liver biopsy and to develop a standardized patient-tailored predictive model for the management of negative biopsy results. MATERIALS AND METHODS. We retrospectively included 389 patients (mean age ± SD, 62 ± 12 years old) who had undergone US-guided liver biopsy of 405 liver lesions between January 1, 2013, and June 30, 2015. We collected multiple patient- and procedure-related variables. By comparing pathology reports of biopsy and the reference standard (further histology or imaging follow-up), we were able to categorize the biopsy r…

AdultImage-Guided BiopsyMalemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingFalse Negative Result030218 nuclear medicine & medical imaging03 medical and health sciencesCore biopsyFalse-negative result0302 clinical medicineBiopsymedicineHumansFalse Negative ReactionsUltrasonography InterventionalAgedRetrospective StudiesAged 80 and overFine-needle aspirationmedicine.diagnostic_testUS-guided liver biopsybusiness.industryLiver DiseasesDecision TreesUltrasoundnutritional and metabolic diseasesGeneral MedicineMiddle AgedPatient managementDiagnostic errorFine-needle aspiration030220 oncology & carcinogenesisLiver biopsyFemaleRadiologybusinessCore biopsyDecision tree model
researchProduct

Double Retrotransverse Foramen of Atlas (C1)

2018

Background The retrotransverse foramen is a nonmetric variant of C1 that consists of an abnormal accessory foramen on the posterior root of the transverse process. Case Description During a study on the prevalence of the retrotransverse foramen in 150 dry C1 vertebrae, we observed an exceptional C1 (0.67%) with a right double retrotransverse foramen of the 14 C1 vertebrae (9.3%). This has not been reported previously in the literature. No osteogenic reaction and no degenerative signs were observed in this C1 with the double retrotransverse foramen. Conclusions Neurosurgeons should be aware of the possible presence of the “conventional” retrotransverse foramen and the “exceptional” double re…

AdultMale0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesYoung Adult03 medical and health sciences0302 clinical medicinestomatognathic systemAtlas (anatomy)ForamenHumansMedicineProspective StudiesCervical AtlasAgedAged 80 and overbusiness.industryAnatomyMiddle AgedCase descriptionmusculoskeletal systemCervical spinePatient managementbody regionsmedicine.anatomical_structureFemaleSurgery030101 anatomy & morphologyNeurology (clinical)businessPosterior root030217 neurology & neurosurgeryWorld Neurosurgery
researchProduct

Cisplatin preparation error; patient management and morbidity

2009

Introduction. Antineoplastic drug therapy errors represent a high iatrogenic potential due to antineoplastic drugs narrow therapeutic ranges and the complexity of chemotherapy regimens that may increase the risk of morbidity and mortality for oncology patients.Setting. We report a 57-year-old man with head and neck cancer who mistakenly received 180 mg/ m2of cisplatin overdose despite the safety measures and validations carried out during preparation. The patient developed moderate nausea and vomiting, acute renal failure, hearing difficulty (tinnitus), and severe myelodepression.Patient management. Prophylactic and symptomatic treatments were applied in order to prevent and correct toxicit…

AdultMalemedicine.medical_specialtyNauseaDrug CompoundingAntineoplastic drugmedicine.medical_treatmentAntineoplastic AgentsDrug overdoseMedication errorTinnitusmedicineHumansPharmacology (medical)Intensive care medicineBone Marrow DiseasesCisplatinChemotherapyMedical Errorsbusiness.industryNauseaAcute Kidney Injurymedicine.diseasePatient managementSurgeryOncologyHead and Neck NeoplasmsAntineoplastic DrugsCisplatinDrug Overdosemedicine.symptombusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Complications following the use of alloplastic materials in urogynecological surgery

2011

Abstract Study design 118 patients, who were admitted from 2005 to 2008 to our department due to complications following mesh implantation, were included in a retrospective survey. We investigated patient symptoms, findings and subsequent patient management. There was a re-evaluation of symptoms in a follow-up eight weeks after the revision procedure. Data from our urogynecological file archive were used. Results The main complaints were de novo urgency, pain and recurrent urinary tract infections. The main findings were mesh erosion and infections including abscess formations and osteomyelitis. Before being admitted to our department, 42 patients (35.6%) had already undergone at least one …

Adultmedicine.medical_specialtyReferralRevision procedureUrinary Incontinence StressUrinary systemPelvic Organ ProlapseGynecologic Surgical ProceduresRetrospective surveymedicineHumansMesh erosionAbscessDevice RemovalAgedRetrospective StudiesAged 80 and overSuburethral Slingsbusiness.industryOsteomyelitisObstetrics and GynecologyMiddle AgedSurgical Meshmedicine.diseasePatient managementSurgeryReproductive MedicineUrologic Surgical ProceduresFemalebusinessEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant facto…

2008

Summary.  The intention of the ‘clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis’ (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn…

Adultmedicine.medical_specialtyTime FactorsAdolescentObjective dataFactor VIIaHemophilia AHaemophiliaDrug Administration ScheduleYoung AdultClinical ProtocolsHemarthrosisActivated factor VIIHumansMedicineRange of Motion ArticularIntensive care medicineGenetics (clinical)UltrasonographyProtocol (science)Blood Coagulation Factor Inhibitorsbiologybusiness.industryObjective methodHematologyGeneral Medicinemedicine.diseaseArthralgiaBlood Coagulation FactorsRecombinant ProteinsPatient managementEuropeRecombinant factor VIIaQuality of Lifebiology.proteinPhysical therapyBlood Coagulation TestsbusinessClinical evaluationHaemophilia
researchProduct

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management.

2013

Endoscopic ultrasonography (EUS) has recently gained a pivotal role in the management of gastric lymphomas, especially in the diagnostic workup. Its accuracy and reliability have overcome those of other imaging techniques, such that it represents an invaluable tool for the management of gastric lymphomas. Although this technique is operator dependent, its application in large series has proved its reliability. Thus, it has generally been considered a useful tool for providing information crucial in deciding the treatment program, especially for mucosa-associated lymphoid tissue (MALT) lymphomas, for which EUS can provide an accurate evaluation of disease extension and treatment response pro…

Cancer Researchmedicine.medical_specialtyTreatment responseDecision MakingEndoscopic ultrasonographyDiseaseGastroenterologyEndosonographyStomach NeoplasmsSubmucosaInternal medicinemedicineHumansNeoplasm Stagingbiologybusiness.industryGastric lymphomaStomachLymphoma Non-HodgkinDisease ManagementHematologyHelicobacter pylorimedicine.diseasebiology.organism_classificationPrognosisdigestive system diseasesPatient managementmedicine.anatomical_structureTreatment OutcomeOncologyRadiologybusinessClinical lymphoma, myelomaleukemia
researchProduct

FOCAL LIVER LESIONS: CONTRAST-ENHANCED ULTRASOUND

2008

Contrast-enhanced ultrasound (CEUS) represents a significant breakthrough in sonography and it is being increasingly used for evaluation of focal liver lesions (FLLs). The unique feature of CEUS of non-invasively assessing in real time liver perfusion throughout the vascular phase has led to a dramatic improvement in diagnostic accuracy of US in either detection and characterization of FLLs, as well as in the guidance and evaluation of response of therapeutic procedures. Currently, CEUS is included as a part of the suggested diagnostic work-up of FLLs, resulting in a better patient management and cost-effective therapy delivering. After a brief description of the basis of different CEUS tec…

Echinococcosis HepaticLiver perfusionmedicine.medical_specialtyUrologyLiver AbscessClinical settingsDiagnostic accuracySensitivity and SpecificityLiver neoplasmAdenoma Liver CellLiver diseaseInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingUltrasonography Doppler ColorUltrasound contrast mediaRadiological and Ultrasound TechnologyCystsbusiness.industryLiver DiseasesLiver NeoplasmsUltrasoundGastroenterologyUltrasonography DopplerGeneral MedicineHepatologyImage Enhancementmedicine.diseaseContrast-enhanced sonographyPatient managementFatty LiverFocal Nodular HyperplasiaUltrasonography Doppler PulsedRadiologyLiver sonographyHemangiomabusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaLiver diseaseContrast-enhanced ultrasound
researchProduct

Reply to the letter to the editor ‘How much evidence isn't in evidence-based guidelines?’ by Johnson et al.

2015

ABSTRACT ESMO produces pan-European, multidisciplinary, peer-reviewed and updatable guidelines with global impact on current clinical practice, with the intention of providing the practising health professional in cancer care with an easy to use, evidence-based tool for optimal patient management. Levels of evidence and strength of recommendation metrics are provided. In the Dyspnoea ESMO CPG, we strove to fulfill these targets, though we accept any productive criticism that will contribute to the improvement of the product.

Lung NeoplasmsLetter to the editorEvidence-based practiceHealth professionalsbusiness.industryMedizinHematologyEvidence-based medicinePatient managementClinical Practice03 medical and health sciencesDyspnea0302 clinical medicineOncologyNursingMultidisciplinary approach030220 oncology & carcinogenesisHumansCriticismMedicine030212 general & internal medicinebusinessAnnals of Oncology
researchProduct